Ratings for Stoke Therapeutics (NASDAQ:STOK) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 5 0 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 3 0 0 0 0 3M Ago 1 0 0 0 0 Analysts have set 12-month price targets for Stoke Therapeutics, revealing an average target of $24.2, a high estimate of $35.00, and a low estimate of $20.00. Experiencing a 3.2% decline, the current average is now lower than the previous average price target of $25.00. Understanding Analyst Ratings: A Comprehensive Breakdown A clear picture of Stoke Therapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Joseph Stringer Needham Maintains Buy $22.00 $22.00 Andrew Fein HC Wainwright & Co. Maintains Buy $35.00 $35.00 Sumant Kulkarni Canaccord Genuity Lowers Buy $20.00 $21.00 Joseph Stringer Needham Maintains Buy $22.00 $22.00 Joseph Stringer Needham Maintains Buy $22.00 - Key Insights: Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their ...Full story available on Benzinga.com

Stoke Therapeutics (NASDAQ:STOK) underwent analysis by 8 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 6 1 1 0 0 Last 30D 1 0 0 0 0 1M Ago 1 0 0 0 0 2M Ago 3 1 1 0 0 3M Ago 1 0 0 0 0 Analysts have recently evaluated Stoke Therapeutics and provided 12-month price targets. The average target is $20.75, accompanied by a high estimate of $35.00 and a low estimate of $13.00. Witnessing a positive shift, the current average has risen by 62.75% from the previous average price target of $12.75. Understanding Analyst Ratings: A Comprehensive Breakdown A comprehensive examination of how financial experts perceive Stoke Therapeutics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Joseph Stringer Needham Maintains Buy $22.00 - Joseph Stringer Needham Maintains Buy $22.00 - Laura Chico Wedbush Raises Outperform $17.00 $13.00 Sumant Kulkarni Canaccord Genuity Raises Buy $21.00 $18.00 Jessica Fye JP Morgan Raises Neutral $13.00 $6.00 Andrew Fein HC Wainwright & Co. Maintains Buy $35.00 - Joseph Stringer Needham Raises Buy $22.00 $14.00 Joseph Stringer Needham Maintains Buy $14.00 - Key Insights: Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Stoke Therapeutics. This information ...Full story available on Benzinga.com

Stoke Therapeutics (STOK) delivered earnings and revenue surprises of 5% and 26.61%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Stoke Therapeutics (STOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 analysts have expressed a variety of opinions on Stoke Therapeutics (NASDAQ:STOK) over the past quarter, offering a diverse set of opinions from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 1 1 0 0 Last 30D 0 0 0 0 0 1M Ago 3 1 1 0 0 2M Ago 1 0 0 0 0 3M Ago 0 0 0 0 0 In the assessment of 12-month price targets, analysts unveil insights for Stoke Therapeutics, presenting an average target of $20.33, a high estimate of $35.00, and a low estimate of $13.00. This upward trend is apparent, with the current average reflecting a 59.45% increase from the previous average price target of $12.75. Deciphering Analyst Ratings: An In-Depth Analysis The standing of Stoke Therapeutics among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Laura Chico Wedbush Raises Outperform $17.00 $13.00 Sumant Kulkarni Canaccord Genuity Raises Buy $21.00 $18.00 Jessica Fye JP Morgan Raises Neutral $13.00 $6.00 Andrew Fein HC Wainwright & Co. Maintains Buy $35.00 - Joseph Stringer Needham Raises Buy $22.00 $14.00 Joseph Stringer Needham Maintains Buy $14.00 - Key Insights: Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it ...Full story available on Benzinga.com

Stoke Therapeutics' stock soars as positive data shows potential for their lead drug candidate, STK-001, in treating Dravet syndrome. Read here for more details.

Stoke Therapeutics (STOK) gains on meaningful clinical data from STK-001 studies for the treatment of Dravet syndrome.

Stoke Therapeutics Inc (NASDAQ:STOK) shares are rising in Tuesday’s after-hours session, riding a wave a momentum higher despite announcing a proposed public offering after the bell. What To Know: After the market close on Tuesday, Stoke Therapeutics announced a proposed underwritten public offering of up to $75 million of its common stock. The company also intends to grant the underwriters a 30-day window to purchase up to an additional 15% of the shares in the public offering. Stoke said it expects to use the net proceeds to fund ...Full story available on Benzinga.com

U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining over 80 points on Tuesday. The Dow traded up 0.21% to 39,397.20 while the NASDAQ rose 0.23% to 16,421.62. The S&P 500 also rose, gaining, 0.17% to 5,227.03. Check This Out: Top 3 Energy Stocks That May Keep You Up At Night In Q1   Leading and Lagging Sectors   Consumer discretionary shares jumped by 0.6% on Monday. In trading on Monday, utilities shares fell by 1%.   Top Headline   TD SYNNEX Corporation (NYSE: SNX) reported better-than-expected first-quarter earnings. The company reported first quarter adjusted earnings per share of $2.99, beating the street view of $2.84. The company reported quarterly revenue of $13.975 billion, missing the analyst view of $14.357 billion.   Equities Trading UP   Stoke Therapeutics, Inc. (NASDAQ: STOK) shares shot up 72% to $11.19 after the company announced Phase 1/2a data supporting the potential for STK-001 in Dravet syndrome. Shares of Mesoblast Ltd (NASDAQ: MESO) got a boost, surging 66% to $3.6420 after the FDA informed the company that the available clinical data from its Phase 3 study MSB-GVHD001 appears sufficient to ...

Shares of Westport Fuel Systems Inc. (NASDAQ: WPRT) fell sharply during Tuesday’s session after posting a wider-than-expected fourth-quarter loss. Westport Fuel Systems posted a quarter loss of 81 cents per share, compared to market expectations for a loss of 51 cents per share. Westport Fuel Systems shares dipped 9.9% to $6.52 on Monday. Here are some other stocks moving in today's mid-day session. Gainers Stoke Therapeutics, Inc. (NASDAQ: STOK) shares gained 72.6% to $11.24 after the company announced Phase 1/2a data supporting the potential for STK-001 in Dravet syndrome. C3is Inc. (NASDAQ: CISS) climbed 65% to $0.0581 after the company reported a year-over-year increase in fourth-quarter financial results. OpGen, Inc. (NASDAQ: OPGN) shares climbed 48.2% to $0.7039 after the company entered into a securities purchase agreement with a private investor, David Lazar, to acquire 3 million shares of Series E Convertible Preferred Stock at $1.00 per share for aggregate gross proceeds of $3.0 million. Mesoblast Limited (NASDAQ: MESO) gained 43.2% to $3.1501. Mesoblast was notified by the U.S. FDA that available clinical data from Phase 3 trial appear sufficient to support BLA submission for Remestemcel-L in children with steroid-refractory acute graft versus host disease. Praxis Precision Medicines Inc (NASDAQ: PRAX) gained 31.9% to $66.63 after the company reported results from a Phase 2a proof of concept study evaluating PRAX-628 in epilepsy patients with PPR. Nuvation Bio Inc (NYSE: NUVB) climbed 24.4% to $2.80 after BTIG upgraded the stock from Neutral to Buy. Check-Cap Ltd. (NASDAQ: CHEK) shares gained 24.3% to $2.40 after the company announced that it entered into a definitive Business Combination Agreement with Nobul AI. Viking Therapeutics ...

U.S. stocks traded higher midway through trading, with the Dow Jones gaining around 100 points on Tuesday. The Dow traded up 0.25% to 39,413.30 while the NASDAQ rose 0.27% to 16,448.55. The S&P 500 also rose, gaining, 0.27% to 5,232.36. Check This Out: Top 3 Energy Stocks That May Keep You Up At Night In Q1   Leading and Lagging Sectors   Consumer discretionary shares jumped by 0.8% on Monday. In trading on Monday, energy shares fell by 0.6%.   Top Headline   McCormick & Co Inc (NYSE: MKC) reported better-than-expected first-quarter financial results. McCormick reported first-quarter FY24 sales growth of 3% year-on-year to $1.60 billion, beating the analyst consensus estimate of $1.56 billion. Adjusted EPS of 63 cents beat the consensus of 58 cents.   Equities Trading UP   Stoke Therapeutics, Inc. (NASDAQ: STOK) shares shot up 73% to $11.25 after the company announced Phase 1/2a data supporting the potential for STK-001 in Dravet syndrome. Shares of Mesoblast Ltd (NASDAQ: MESO) got a boost, surging 36% to $3.00 after the FDA informed the company that the available clinical data from its Phase 3 study MSB-GVHD001 appears sufficient to support ...